ea0090rc10.1 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023
Casals Gregori
, Lecue Elena
, Shahbazi Shayan
, Guo Dongdong
, Perramon Meritxell
, Zeng Muling
, Jimenez Wladimiro
, Morales-Ruiz Manuel
, Casals Eudald
, Fernandez-Varo Guillermo
Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by the presence of hepatic steatosis, which can progress to non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma. There are no licensed therapies to halt MAFLD progression, despite it is becoming the most important etiology for advanced liver disease.Aim: The aim of the study was to evaluate the therapeutic potential of inorganic nanopartic...